It is with great pleasure that Mologic Ltd t/a Global Access Diagnostics (GADx), announces the appointment of our new CEO, starting 1st February 2024, Dr Mark Street-Docherty.
Mark brings with him enormous experience of leading small and medium-sized diagnostic companies in the UK and enters GADx at a time of significant growth.
‘I am delighted to join GADx as their new CEO, and excited to be working with the restructured senior leadership team towards our goals of providing innovation solutions for point-of-care diagnostics.’
– Dr Mark Street-Docherty
Mark is a seasoned IVD professional with extensive experience of the design, manufacture and global deployment of clinical diagnostics. He has previously served as CEO and Executive Chair at several UK businesses, including the award-winning Elucigene Diagnostics business. His wide experience of building diagnostics businesses will play an important role in the mission of the parent organization, Global Access Health, to manufacture its products in Africa and South East Asia with local partners.
GADx is owned by a consortium of social impact investors called Global Access Health, dedicating its profits and mission to improving the health and wellbeing of underserved populations around the world. Headquartered in Bedford in the United Kingdom, with a US subsidiary situated in Maine, New Gloucester.
Since May 2023 GADx has been managed in collaboration with the Clinton Health Access Initiative team’s Dr Randy Allen and Mr Alan Staple, who have brought enormous experience, expertise, and systems. GADx and our Board members are grateful for all their support and commitment during this transition period.
GADx is now entering a period of substantial revenue growth through the delivery of contract product development services of companion diagnostics for top-tier pharmaceutical partners and through delivery on contracts to develop diagnostics and diagnostic technologies for Global Health.